James E. Egan PhD MBA, President and CEO
| Phone: 516-449-8148
Dr. Egan has extensive experience in both academic and commercial drug development. Most recently Dr. Egan has served as Director of Business development at IRX Therapeutics, a clinical stage biopharmaceutical company. IRX focused on therapies for the treatment of cancer and chronic infectious diseases. In this role he was responsible for raising over $90mm to fund the development of their lead product. Dr. Egan negotiated the option to sell the company to Celgene Corporation in 2013. Other responsibilities included every facet of drug development including fundraising from financial investors, marketing and out-licensing clinical opportunities to strategic partners, alliance management with strategic partners and external research collaborators, managed intellectual property portfolio, oversaw internal and external research programs and collaborated with the clinical development team to de-risk and generate proof-of-concept for products in our pipeline. Prior to joining IRX Therapeutics, Dr. Egan worked at Cold Spring Harbor Laboratories and consulted for Alliance Capital Management. This experience has provided Dr. Egan with the skills to integrate both the scientific and financial issues involved in successful drug development, devise strategic alternatives and execute on the plan.
Dr. Egan received a PhD in Molecular Pharmacology from Stony Brook University and an MBA in Management and Finance from Stony Brook University.
Iwao Ojima PhD, Scientific Advisor
Dr. Ojima BS, M.S, PhD has served as the Consultant of E. I. du Pont, Eli Lilly, Air Products & Chemicals, Mitsubishi Chem. Corp., Ajinomoto Co., Inc., Ajinomoto Pharmaceuticals Co., Ltd., Nippon Steel Corp., Life Science Division, Rhone-Poulenc Rorer, ImmunoGen, Inc., Taiho Pharmaceutical Co., Milliken & Co., Aventis Pharma, OSI Pharmaceuticals, Inc., Central Glass Co., Ltd. Dr. Ojima is an internationally recognized expert in medicinal chemistry, including anticancer agents, antibacterial agents and enzyme inhibitors, development of efficient synthetic methods for organic synthesis by means of organometallic reagents, homogeneous catalysis and organometallic chemistry, peptide and peptide mimetics, beta-lactam chemistry, and organoflourine chemistry at the biomedical interface. Dr. Ojima is Distinguished Professor of Chemistry and Director of Institute of Chemical Biology and Drug Discovery, SUNY-Stony Brook. Dr. Ojima is a Member of the American Chemical Society, American Association for the Advancement of Science, American Association for Cancer Research, American Peptide Society, Chemical Society of Japan, Society of Synthetic Organic Chemistry, Japan, New York Academy of Sciences, and Sigma Xi.. Dr. Ojima is a recipient of the Arthur C. Cope Scholar Award in 1994, the E. B. Hershberg Award (for important discovery of medicinally active substances) in 2001, and the ACS Award for Creative Work in Fluorine Chemistry from the American Chemical Society; The Chemical Society of Japan Award (for distinguished achievements) in 1999, Outstanding Inventor Award from the Research Foundation of the State University of New York in 2002. Dr. Ojima was inducted to the American Chemical Society Medicinal Chemistry Hall of Fame in 2006. Dr. Ojima is a Fellow of the J.S. Guggenheim Memorial Foundation since 1995, the American Association for the Advancement of Science since 1997, The New York Academy of Sciences since 2000, and the American Chemical Society since 2010.
Mansoor Amiji, PhD Scientific Advisor
Dr. Mansoor Amiji is Distinguished Professor and Chair of Pharmaceutical Sciences in the School of Pharmacy at Northeastern University. He has over 20 years of experience in nanotechnology, polymeric biomaterials, and drug/gene delivery systems. His lab at Northeastern University has made seminal contributions in the area of multifunctional nanosystems for tumor-targeted delivery of small molecules and nucleic acids (plasmid DNA and small interfering RNA). Dr. Amiji is also the Co-Director of Northeastern University’s Nanomedicine Education and Research Consortium (NERC), which was established after acquisition of an NCI/NIH and NSF co-funded Interdisciplinary Graduate Education and Research Training (IGERT) grant in 2005.